The U.S. Food and Drug Administration has approved IDVYNSO, a new once-daily, single-tablet regimen developed by Merck, for the treatment of adults living with HIV-1. The therapy is designed as a replacement option for patients who are already virologically suppressed on a stable antiretroviral regimen, offering a simplified and potentially more flexible treatment alternative.
IDVYNSO combines 100 mg of doravirine and 0.25 mg of islatravir into a two-drug regimen. It is specifically indicated for patients whose viral load is well controlled—defined as HIV-1 RNA levels below 50 copies per milliliter—and who have no history of treatment failure or resistance to doravirine. The drug is expected to be available in pharmacies after May 11.
The approval marks a notable development in HIV care, particularly as patient needs evolve over time. Carl Baloney Jr., president and CEO of AIDS United, emphasized that while advances in treatment have significantly extended life expectancy for people living with HIV, aging patients often face additional health challenges. These include managing multiple chronic conditions and complex medication regimens, making simplified treatment options increasingly important.
From a clinical innovation perspective, IDVYNSO introduces a distinct therapeutic approach. Eliav Barr, senior vice president and chief medical officer at Merck Research Laboratories, highlighted that the regimen combines a next-generation nucleoside reverse transcriptase inhibitor (NRTI), islatravir, with doravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Notably, it is the only approved two-drug regimen that is both non-INSTI and free of tenofovir, expanding treatment diversity beyond current oral options.
Clinical evidence supporting the approval comes from two Phase 3 trials, which demonstrated that IDVYNSO is non-inferior to existing standard therapies. In these studies, a high percentage of participants maintained viral suppression after switching to the new regimen. In one trial, 92% of patients on IDVYNSO remained suppressed at 48 weeks, compared to 94% on a standard regimen. In another, 96% of patients maintained suppression, compared to 92% in the control group.
Safety findings were generally comparable to existing therapies, with low discontinuation rates due to adverse events. However, the treatment carries warnings, including potential severe skin reactions such as Stevens-Johnson syndrome, as well as possible drug interactions that could reduce effectiveness or increase side effects. IDVYNSO is contraindicated with certain medications, including strong CYP3A enzyme inducers.
Experts say the approval could provide an important alternative for patients seeking to switch therapies. Amy Colson, director of research at the Community Resource Initiative in Boston, noted that IDVYNSO’s comparable efficacy to established regimens—including BIKTARVY—positions it as a viable option for individuals who may benefit from a different treatment profile.
In addition to the drug’s clinical benefits, Merck has launched a patient support initiative, the Merck Access Program, to assist with insurance navigation, co-pay support, and access to treatment. The program aims to ensure that eligible patients can obtain the therapy without significant financial barriers.
Overall, the approval of IDVYNSO reflects continued progress in HIV treatment innovation, with a growing focus on personalized care, long-term management, and improved quality of life for people living with the virus.